Senores Pharma Q3 Results: Shares zoom 17% as profit more than doubles; income up 35%

In Regulated Markets, robust growth in the CDMO and CMO segment was partly offset by a softer performance in the Marketed Products segment, which was impacted by the high base of Q3FY24.